Calibrating Observational Health Record Data Against a Randomized Trial
In this cohort study piloting an RCT emulation, results were incongruous with the benchmark trial. Differences in patient treatment and data capture between the RCT and EHR populations, confounding by indication, treatment crossover, and accuracy of captured diagnoses may explain these findings. Future feasibility assessments will require data sources to have important oncology-specific measures curated.
Authors
- Chithra Sangli
- Simone Pinheiro (ORCID: https://orcid.org/0000-0002-9360-1379)
- Sebastian Schneeweiß (ORCID: https://orcid.org/0000-0003-2575-467X)
- Asher Wasserman (ORCID: https://orcid.org/0000-0003-4235-3595)
- Rachele Hendricks‐Sturrup (ORCID: https://orcid.org/0000-0002-3390-2583)
- Ulka B. Campbell (ORCID: https://orcid.org/0000-0002-3503-8178)
- Osayi E. Ovbiosa (ORCID: https://orcid.org/0000-0003-1869-9908)
- David Lenis (ORCID: https://orcid.org/0000-0001-8697-1737)
- Joy C. Eckert
- Carla V. Rodriguez
- Yiduo Zhang (ORCID: https://orcid.org/0000-0002-1978-9713)
- Mark A. Shapiro (ORCID: https://orcid.org/0000-0002-7611-5432)
- Lauren B. Becnel (ORCID: https://orcid.org/0000-0002-4899-1777)
- Sajan Khosla (ORCID: https://orcid.org/0000-0002-5114-1968)
- Ann M. Madsen (ORCID: https://orcid.org/0000-0002-9206-708X)
- Megan Rees (ORCID: https://orcid.org/0000-0002-7736-4000)
- Shirley Wang (ORCID: https://orcid.org/0000-0001-7761-7090)
- Lynn McRoy
- K. Arnold Chan (ORCID: https://orcid.org/0000-0001-8161-1986)
- Mark Stewart (ORCID: https://orcid.org/0000-0002-4847-0736)
- Joel Greshock (ORCID: https://orcid.org/0000-0001-6567-4266)
- Brian San Francisco
- Andrew J. Belli
- Orsolya Lunacsek (ORCID: https://orcid.org/0000-0003-4872-9813)
- Nelson D. Pace (ORCID: https://orcid.org/0000-0002-6925-1444)
- Khaled Sarsour
- Gillis Carrigan (ORCID: https://orcid.org/0000-0002-7973-3607)
- Amanda Bruno (ORCID: https://orcid.org/0009-0007-6721-2234)
- Ben Taylor (ORCID: https://orcid.org/0000-0001-6101-3786)
- Neil Dhopeshwarkar (ORCID: https://orcid.org/0000-0001-6305-256X)
- Jennifer R. Rider (ORCID: https://orcid.org/0000-0002-2637-6036)
- Raymond A. Harvey
- Mothaffar F. Rimawi (ORCID: https://orcid.org/0000-0002-4284-5656)
- Jameson Quinn (ORCID: https://orcid.org/0000-0002-7267-3170)
- Laura L. Fernandes (ORCID: https://orcid.org/0000-0002-5986-3885)
- David Merola (ORCID: https://orcid.org/0000-0003-0528-0956)
- Aliki Taylor (ORCID: https://orcid.org/0000-0002-4863-9810)
- James Chen (ORCID: https://orcid.org/0000-0001-5053-6151)
- Jenny Huang
- Yana Natanzon
- Travis Robinson
- Victoria Chia
- Churou Wang
- Xiaolong Jiao
Institutions
- Brigham and Women's Hospital (US)
- Amgen (United States) (US)
- Johnson & Johnson (United States) (US)
- Harvard University (US)
- Bayer (United States) (US)
- Pfizer (United States) (US)
- Baylor College of Medicine (US)
- Reagan-Udall Foundation (US)
- AbbVie (United States) (US)
- Center for Neuro-Oncology (US)
- Aetion (United States) (US)
- EP Analytics (United States) (US)
- Concert Pharmaceuticals (United States) (US)
- Tempus Labs (United States) (US)
- Gilead Sciences (United States) (US)
- AstraZeneca (United States) (US)
- TriNetX (United States) (US)
- Medidata (United States) (US)
- Friends of Cancer Research (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.36535
- Citations
- 7
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.93